Learning Objectives:

  1. Review the management of resectable gastroesophageal adenocarcinoma (GEA)

  2. Describe the use of immunotherapy in GEA and biomarkers predictive of response to PD-1 blockade

  3. Discuss a clinical trial investigating neoadjuvant pembrolizumab in cT1-2N0M0 resectable GEA




1. Discuss the T cell-inflamed and non-T cell-inflamed tumor phenotype as a framework for identifying mechanisms of immunotherapy resistance.

2. Identification of oncogene pathways associated with non-T cell-inflamed tumors and that mediate immune exclusion.
3. Investigate whether tumor-intrinsic hypoxia-inducible factor-1 alpha (HIF1-alpha) activation mediates T cell exclusion from the tumor microenvironment.

Session date: 
12/18/2017 - 12:00pm to 1:00pm CST
University of Chicago Medicine
5841 South Maryland Avenue
MC2115, Conference Room E-215
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Smitha Joshi, MD and Jonathan Trujillo, MD